News - STC-15 - LARVOL VERI

7ms

STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers (clinicaltrials.gov)

P1/2, N=188, Recruiting, STORM Therapeutics LTD

7 months ago

New P1/2 trial

Loqtorzi (toripalimab-tpzi) • STC-15

9ms

STC15-22101: Oral Administration of STC-15 in Subjects with Advanced Malignancies (clinicaltrials.gov)

P1, N=42, Completed, STORM Therapeutics LTD | Active, not recruiting --> Completed | Trial completion date: Mar 2025 --> Dec 2024 | Trial primary completion date: Dec 2024 --> Aug 2024

9 months ago

Trial completion • Trial completion date • Trial primary completion date

STC-15

1year

Phase 1 dose escalation and cohort expansion study evaluating safety, PK, PD and clinical activity of STC-15, a METTL3 inhibitor, in patients with advanced malignancies (SITC 2024)

Salus IRB, Protocol STC15-22101. All patients gave informed consent before participation.

1 year ago

P1 data • Clinical • Metastases

METTL3 (Methyltransferase Like 3)

nCounter® PanCancer IO 360™ Panel

STC-15

over1year

STC15-22101: Oral Administration of STC-15 in Subjects With Advanced Malignancies (clinicaltrials.gov)

P1, N=42, Active, not recruiting, STORM Therapeutics LTD | Recruiting --> Active, not recruiting | N=66 --> 42 | Trial primary completion date: May 2024 --> Dec 2024

over 1 year ago

Enrollment closed • Enrollment change • Trial primary completion date • Metastases

METTL3 (Methyltransferase Like 3)

STC-15

almost2years

Oral Administration of STC-15 in Subjects With Advanced Malignancies (clinicaltrials.gov)

P1, N=66, Recruiting, STORM Therapeutics LTD | Trial completion date: Dec 2024 --> May 2025 | Trial primary completion date: Dec 2023 --> May 2024

almost 2 years ago

Trial completion date • Trial primary completion date • Metastases

METTL3 (Methyltransferase Like 3)

STC-15

2years

Oral Administration of STC-15 in Subjects With Advanced Malignancies (clinicaltrials.gov)

P1, N=66, Recruiting, STORM Therapeutics LTD | Trial completion date: Sep 2024 --> Dec 2024 | Trial primary completion date: Sep 2023 --> Dec 2023

2 years ago

Trial completion date • Trial primary completion date • Metastases

STC-15

over2years

Discovery of STC15, an orally bioavailable, highly selective METTL3 inhibitor for the treatment of AML and solid tumours: The first molecule specifically targeting an RNA methyltransferase enzyme to enter clinical development (ACS-Fall 2023)

This work has delivered the first RNA methyltransferase inhibitor into the clinic. We will describe the discovery of METTL3 inhibitor STC15 and share emerging data from the phase one clinical trial.

over 2 years ago

Clinical

METTL3 (Methyltransferase Like 3)

STC-15

3years

STC-15, an oral small molecule inhibitor of the RNA methyltransferase METTL3, inhibits tumour growth through activation of anti-cancer immune responses and synergises with immune checkpoint blockade (SITC 2022)

These data provide the rationale for the development of STC-15 both as monotherapy and in combination with checkpoint inhibition for the treatment of solid tumour malignancies. A Phase I, First-in-Human clinical trial is planned to begin in 2022 Ethics Approval Animal welfare for this study complies with the UK Animals Scientific Procedures Act 1986 (ASPA) in line with Directive 2010/63/EU of the European Parliament and the Council of 22 September 2010 on the protection of animals used for scientific purposes.

3 years ago

Checkpoint inhibition

CD8 (cluster of differentiation 8) • METTL3 (Methyltransferase Like 3)

STC-15

over3years

STC-15, an oral small molecule inhibitor of the RNA methyltransferase METTL3, inhibits tumour growth through activation of anti-cancer immune responses associated with increased interferon signalling, and synergises with T cell checkpoint blockade (AACR-NCI-EORTC 2022)

over 3 years ago

Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker

METTL3 (Methyltransferase Like 3)

STC-15